Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine

Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors:  Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1<i>H</i>-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)

Thomas D. Penning, John J. Talley, Stephen R. Bertenshaw et al. · Journal of Medicinal Chemistry · 1997 · 2K citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Gastrointestinal Damage Associated with the Use of Nonsteroidal Antiinflammatory Drugs

M C Allison, Allan G. Howatson, Caroline J. Torrance et al. · New England Journal of Medicine · 1992 · 962 citations · Full text

Medicine, Internal Medicine, Pharmacology +11

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib:  A Potent and Selective Inhibitor of COX-2

John J. Talley, David Brown, Jeffery S. Carter et al. · Journal of Medicinal Chemistry · 2000 · 643 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +8

Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs.

Odette Laneuville, D.K. Breuer, David L. DeWitt et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 472 citations

Medicine, Pharmacology, Pharmacotherapy +17

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9